Business, energy, technology, markets and global industry news from Business News Today

Nature Communications

PharmaDeviceNews Nature Communications
A Nature Communications study found Vascudyne’s externally supported bioengineered vessel remained patent for up to 550 days in sheep, including about a year without anticoagulation, supporting further evaluation of its long-term vascular graft potential. Representative image.
Medical Devices & Diagnostics

Could CABG stop depending on harvested veins? Vascudyne’s 18-month data strengthen the case.

A Nature Communications study found Vascudyne’s externally supported bioengineered vessel remained patent for up to 550 days in sheep, including a year without anticoagulation.

Read More
A representative image illustrating Rein Therapeutics’ LTI-03 idiopathic pulmonary fibrosis program as the FDA grants Fast Track designation and the inhaled therapy advances toward closely watched Phase 2 RENEW data in the second half of 2026.
Pharma & Biotech

LTI-03 gets FDA Fast Track status as Rein heads toward Phase 2 IPF data

FDA grants LTI-03 Fast Track status as Rein advances its 120-patient Phase 2 IPF trial toward a closely watched second-half 2026 readout.

Read More